Search
Zonisamide
go.drugbank.com/drugs/DB00909ApprovedInvestigational[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors … [L42530,L42535] Zonisamide represents an alternative for patients that remain refractory to established antiepileptic drugs. In 1989, it was approved for commercial use in Japan.
Phenylephrine
go.drugbank.com/drugs/DB00388ApprovedInvestigationalPhenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil,[L9413] and induce local vasoconstriction.
Mixtures: Robitussin To Go Cough and Cold CF, Brom TappSynonyms: l-(3-Hydroxyphenyl)-N-methylethanolamineRespiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigationalArexvy (respiratory syncytial virus vaccine, adjuvanted) is an adjuvanted vaccine developed by GlaxoSmithKline Biologicals. … [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]
Lutetium Lu 177 dotatate
go.drugbank.com/drugs/DB13985ApprovedInvestigationalmolecules carrying radioactive particles that bind to specific receptors expressed by the tumour. … Patients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies.
Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigationalSepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria. … It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH
Bosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigational[L48436] On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.
Rabies immune globulin, human
go.drugbank.com/drugs/DB11603ApprovedSince rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun. … Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory
Trolamine
go.drugbank.com/drugs/DB13747ApprovedInvestigationalTrolamine, which is also referred to as triethanolamine (TEA), is a tertiary amine and a triol. It is a bifunctional compound that exhibits both properties of alcohols and amines.
Betibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigationalBetibeglogene autotemcel is an autologous gene therapy that adds functional copies of the β-globin gene (β<sup>A-T87Q</sup>-globin) to hematopoietic stem cells in order to treat β-thalassemia. … The use of betibeglogene autotemcel is more effective in patients with β-thalassemia with residual β-globin synthesis (non-β<sup>0</sup>/β<sup>0</sup> genotype) compared to those with no detectable β-globin
Davesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigationalSimilar to the previous Moderna COVID-19 vaccine, Moderna Bivalent vaccine encodes the full-length pre-fusion stabilized spike (S) protein to elicit an immune response. … [L43882] A phase 2 and 3 open-label study in participants 18 years or older who had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the